Background Castration-resistant prostate cancer (CRPC) occurs when prostate cancer
(CaP) progresses under therapy-induced castrate conditions. Several mechanisms have …

BACKGROUND Significant progress in understanding the molecular basis of castration
resistant prostate cancer (CRPCa) has been achieved in recent years. Despite this progress …

Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical
challenge, even with recent advancements in diagnosis and treatment. To improve patient …

Metastatic castration-resistant prostate cancer (CRPC) is associated with substantial clinical,
pathologic, and molecular heterogeneity. Most tumors remain driven by androgen receptor …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

CONTEXT: Castration-resistant prostate cancer (CRPC) refers to patients who no longer
respond to surgical or medical castration. Standard treatment options are limited …

Context Androgen deprivation therapy (ADT) is the backbone of treatment for advanced
prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably …

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …

Context After initiation of androgen deprivation therapy (ADT), most patients progress to
castration-resistant prostate cancer (CRPC) within 2 or 3 yr. In the USA, approximately 67 …

With increases in the mortality rate and number of patients with prostate cancer (PCa), PCa,
particularly the advanced and metastatic disease, has been the focus of a number of studies …